Please assess the completion status of the following clinical trial:

Trial Title: Study in Parkinson's Disease of Exercise

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of primary Parkinson's disease~* In a Hoehn and Yahr stage less than stage III~* Disease duration is less than 5 years~* Not likely to require dopaminergic therapy within 6 months~Exclusion Criteria:~* Use of any PD medication within 60 days prior to the beginning the study, including levodopa, direct dopamine agonists, amantadine, Rasagiline (Azilect), Selegiline (Eldepryl), Artane (trihexyphenidyl).~* Duration of previous use of medications for PD that exceeds 90 days~* Expected to require dopaminergic therapy in the next 6 months~* Poorly controlled or unstable cardiovascular disease~* Uncontrolled hypertension~* Hypo- or hyperthyroidism, abnormal liver function, abnormal renal function~* Mild cognitive impairment (Montreal Cognitive Assessment score\<26/30)~* Depression that precludes ability to exercise (Beck depression score\>13)~* Disorders that interfere with ability to perform endurance exercises~* Regular participation in vigorous endurance exercise~* Evidence of serious arrhythmias or ischemic heart disease~* Any clinically significant medical condition, psychiatric condition, drug or alcohol abuse, or laboratory abnormality that would, in the judgment of the investigators, interfere with the ability to participate in the study

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Control Group (Type: SHAM_COMPARATOR): Wait listed to moderate or vigorous exercise after 6 months of no exercise.
- Vigorous Exercise (Type: EXPERIMENTAL): Endurance exercise at 80-85% HR max, 4x/wk for 6 months.
- Moderate Exercise (Type: EXPERIMENTAL): Endurance exercise at 60-65% HR max, 4x/wk for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).